FCCC LOGO Faculty Publications
Dysplastic Aberrant Crypt Foci: Biomarkers of Early Colorectal Neoplasia and Response to Preventive Intervention
Cancer Prev Res (Phila). 2020 Mar;13(3) :229-240
PMID: 32132117    PMCID: PMC7080315   
Back to previous list
The discovery of aberrant crypt foci (ACF) more than three decades ago not only enhanced our understanding of how colorectal tumors form, but provided new opportunities to detect lesions prior to adenoma development and intervene in the colorectal carcinogenesis process even earlier. Because not all ACF progress to neoplasia, it is important to stratify these lesions based on the presence of dysplasia and establish early detection methods and interventions that specifically target dysplastic ACF (microadenomas). Significant progress has been made in characterizing the morphology and genetics of dysplastic ACF in both preclinical models and humans. Image-based methods have been established and new techniques that utilize bioactivatable probes and capture histologic abnormalities in vivo are emerging for lesion detection. Successful identification of agents that target dysplastic ACF holds great promise for intervening even earlier in the carcinogenesis process to maximize tumor inhibition. Future preclinical and clinical prevention studies should give significant attention to assessing the utility of dysplastic ACF as the earliest identifiable biomarker of colorectal neoplasia and response to therapy.See all articles in this Special Collection Honoring Paul F. Engstrom, MD, Champion of Cancer Prevention.
1940-6215 Clapper, Margie L ORCID: https://orcid.org/0000-0001-7712-5109 Chang, Wen-Chi L Cooper, Harry S P30 CA006927/CA/NCI NIH HHS/United States Journal Article Review United States Cancer Prev Res (Phila). 2020 Mar;13(3):229-240. doi: 10.1158/1940-6207.CAPR-19-0316.